
Product Data Sheet

Brilliant Violet 605[™] anti-human CD154

Catalog # / Size:	2154130 / 100 tests 2154125 / 25 tests	
Clone:	24-31	
Isotype:	Mouse IgG1, κ	mber
Reactivity:	Human	ell Nu
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605 [™] under optimal conditions. The solution is free of unconjugated Brilliant Violet 605 [™] and unconjugated antibody.	Relative Cell Numbe
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).	6-l hu
Concentration:	Lot-specific	lyr CE 60



6-hour PMA+ionomycin-stimulated human peripheral blood lymphocytes were stained with CD154 (clone 24-31) Brilliant Violet 605™ (filled histogram) or mouse IgG1, κ Brilliant Violet 605™ isotype control (open histogram).

Applications:

Applications:	Flow Cytometry
---------------	----------------

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605[™] excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 605[™] is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes:
Additional reported applications (for the relevant formats) include:
immunofluorescence microscopy^{1,3} and blocking of T cell-dependent B cell differentiation^{1,2,4,5}. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 310812). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 310828) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).

Application 1. Brams P, et al. 2001. Int. Immunopharmacol. 1:277. (Block, IF)

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

References:	2. Rushworth SA, <i>et al.</i> 2002.	. <i>Transplantation</i> 73:635. (Block)
--------------------	--------------------------------------	--

- 3. Berner B, et al. 2000. Ann. Rheum. Dis. 59:190. (IF)
- 4. Nordström T, et al. 2006. J. Leukocyte Biol. 79:319. (Block)
- 5. Zhang AL, et al.2007. Blood doi:10.1182/blood-2007-02-076364. (Block) PubMed
- 6. Kuchen S, *et al.* 2007. *J. Immunol.* 179:5886.
- 7. Matus-Nicodermos R, et al. 2011. J. Immunol. 186:2164. PubMed

Description: CD154 (CD40 ligand) is also known as CD40L, gp39, TRAP and T-BAM. CD40 ligand is a 32-39 kD type II transmembrane glycoprotein. It is a member of the TNF superfamily and is expressed on activated T cells. It has been reported to be important for B cell costimulation following binding of its receptor, CD40. Additionally, binding of CD40L to CD40 on B cells promotes the secretion of immunoglobulin and Ig isotype switching. CD40L is also involved in the regulation of cytokine production by T cells.

Antigen	1. Najafian N, et al. 2003. Expert Opin. Biol. Ther. 3:227.
References:	2. Racke M, et al. 2002. Expert Opin. Ther. Targets. 6:275.

3. Ford G, et al. 1999. J. Immunol. 162:4037.